Open Call HORIZON-JU-IHI-2022-03-05: Digital Health Technologies for the Prevention and Personalised Management of Mental Disorders and their Long-Term Health Consequences

European CommissionMental health disorders represent an area of severe unmet public health need. This has been further negatively impacted by the COVID-19 pandemic, with a substantial increase in the number and severity of people affected for example by anxiety and depression, which places substantial pressures on already strained mental health care systems. People with mental disorders have a reduced life expectancy compared to the general population, and this is linked to a greater risk of developing a range of chronic physical conditions. The long-standing separation of psychiatry from other branches of medicine and the lack of specific training on this issue further contribute to the poor attention dedicated to management of comorbidities of mental health disorders.

Digital health technologies (DHT) applied via electronic devices such as wearable sensors, implanted equipment, and handheld instruments and smartphones have already shown significant promise for the prevention and disease management of chronic conditions (e.g. cardiovascular disease, diabetes, obesity). DHT, by making it possible to virtually perform medical activities that have traditionally been conducted in person, also have the potential to decrease the pressure on healthcare systems and their personnel. Thus, DHT might have the potential to address some of the challenges in the prevention, prediction, monitoring and personalised management of mental disorders and their long-term health consequences, as well as to tackle some of the organisational issues in providing mental health care3.

The scope of this topic is to investigate how DHT might positively impact the healthcare pathway for people with mental disorders.

Applicants should demonstrate how DHT may enable:

  • better prevention and prediction of disorder onset or relapse;
  • better disease management;
  • tackling comorbidities;
  • addressing long-term health consequences (such as cardiovascular disease or diabetes).

The choice of the specific mental disorder should be justified based on unmet public health need, its impact on quality of life of people with mental disorders and their families/caregivers as well as the feasibility and preliminary evidence available on the use and value of DHT.

To contribute to breaking the silos between psychiatry and other medical branches and better address the impact of co-morbidities in people with mental disorders, applicants should consider relevant co-morbidity/ies where DHT data, learnings and technologies are already available and can be further developed/applied to mental disorders. Co-morbidities can significantly exacerbate mental health disorders, impacting quality of life and the development of long-term health consequences The choice of comorbidy/ies must therefore be justified accordingly.

Ways of decreasing the burden on caregivers and families should be considered, and applicants should actively engage these actors as well as the people with mental disorders in addressing critical issues and research questions, including about (sustained) engagement with DHT. Consortia should propose ways to foster the future integration of digital and clinical mental healthcare, as well as how DHT might enhance the outcomes of interventions by social and healthcare professionals while decreasing the burden on the healthcare system. Applicants should adequately describe how they plan to measure such burden.

Resources and learnings from previous initiatives at European and national level (Innovative Medicines Initiative funded4 among others) should be taken into consideration.

Applicants should aim to deliver robust evidence on how DHT may be:

  • made easy to adopt and use in a sustained way for both people with mental disorders, their families/caregivers and health and care providers;
  • effectively incorporated into clinical research and in clinician workflows.

Early engagement with regulators should be sought to ensure the future acceptance and usability of the results for example through scientific advice, qualification advice or qualification opinion.

Applicants are expected to implement activities to achieve all expected outcomes.

Applicants are expected to consider allocating appropriate resources to explore synergies with other relevant initiatives and projects.

Opening date: 13 December 2022

Deadline: 15 March 2023 17:00:00 Brussels time

Deadline Model: single-stage

Type of action: HORIZON Action Grant Budget-Based [HORIZON-AG]

For topic conditions, documents and submission service, please visit:
https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/horizon-ju-ihi-2022-03-05

Most Popular Now

SPARK TSL Acquires Sentean Group

SPARK TSL is acquiring Sentean Group, a Dutch company with a complementary background in hospital entertainment and communication, and bringing its Fusion Bedside platform for clinical and patient apps to...

Can AI Techniques Help Clinicians Assess…

Investigators have applied artificial intelligence (AI) techniques to gait analyses and medical records data to provide insights about individuals with leg fractures and aspects of their recovery. The study, published in...

AI Makes Retinal Imaging 100 Times Faste…

Researchers at the National Institutes of Health applied artificial intelligence (AI) to a technique that produces high-resolution images of cells in the eye. They report that with AI, imaging is...

Standing Up for Health Tech and SMEs: Sh…

AS the new chair of the health and social care council at techUK, Shane Tickell talked to Highland Marketing about his determination to support small and innovative companies, by having...

GPT-4 Matches Radiologists in Detecting …

Large language model GPT-4 matched the performance of radiologists in detecting errors in radiology reports, according to research published in Radiology, a journal of the Radiological Society of North America...

ChatGPT Extracts Data for Ischaemic Stro…

In an ischaemic stroke, an artery in the brain is blocked by blood clots and the brain cells can no longer be supplied with blood as a result. Doctors must...

Experts Propose Specific and Suited Guid…

Current Artificial Intelligence (AI) models for cancer treatment are trained and approved only for specific intended purposes. GMAI models, in contrast, can handle a wide range of medical data including...

Herefordshire and Worcestershire Health …

Herefordshire and Worcestershire Health and Care NHS Trust has successfully implemented Alcidion's Miya Precision platform to streamline bed management workflow across seven community hospitals in Worcestershire. The trust delivers community...

A Shortcut for Drug Discovery

For most human proteins, there are no small molecules known to bind them chemically (so called "ligands"). Ligands frequently represent important starting points for drug development but this knowledge gap...

New Horizon Europe Funding Boosts Europe…

The European Commission has announced the launch of new Horizon Europe calls, with a substantial funding pool of over €112 million. These calls are aimed primarily at pioneering projects in...

Cleveland Clinic Study Finds AI can Deve…

Cleveland Clinic researchers developed an artficial intelligence (AI) model that can determine the best combination and timeline to use when prescribing drugs to treat a bacterial infection, based solely on...

New AI-Technology Estimates Brain Age Us…

As people age, their brains do, too. But if a brain ages prematurely, there is potential for age-related diseases such as mild-cognitive impairment, dementia, or Parkinson's disease. If "brain age...